2023 | Synthekine

Synthekine Presents Preclinical Data at SITC 38th Annual Meeting Demonstrating its IL-12 Partial Agonist, STK-026, Significantly Expands Therapeutic Window

November 2, 2023/in 2023, news/by eallison

November 3, 2023

First Patient Dosed in Phase 1b Clinical Trial of Synthekine’s α/β Biased IL-2, STK-012, for Treatment of Solid Tumors

September 27, 2023/in 2023, news/by David Anderson

September 28, 2023

Synthekine Doses First Patient in Phase 1 Clinical Trial of Orthogonal IL-2 and CD19 CAR-T Combination Therapy, STK-009 + SYNCAR-001, for Treatment of CD19+ Hematologic Malignancies

July 26, 2023/in 2023, news/by David Anderson

July 27, 2023

Synthekine Announces Presentations at AACR 2023 Annual Meeting Showcasing Next Series of Oncology Programs

April 11, 2023/in 2023, news/by David Anderson

April 12, 2023

Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics

January 5, 2023/in 2023, news/by David Anderson

January 6, 2023